OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Living with cancer· Appointment prep

Appointment sheet: Papillary renal cell carcinoma

One page to bring and write on: your details, the questions for Papillary renal cell carcinoma plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Papillary renal cell carcinoma

Prepared with OnCo (onco.cc/prep/papillary-rcc/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

13 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example MET mutation, amplification or chromosome 7 gain, Fumarate hydratase losswith germline FH testing, CDKN2A loss, Germline MET testing in young or multifocal disease), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
Localised
  1. 5.For my situation (localised), which of the standard options do you recommend and why?
Metastatic
  1. 6.For my situation (metastatic), which of the standard options do you recommend and why?
  2. 7.Am I a candidate for Cabozantinib, Savolitinib, Sunitinib or related drugs, and what side effects should I expect?
Hereditary syndromes
  1. 8.For my situation (hereditary syndromes), which of the standard options do you recommend and why?
Any stage
  1. 9.Are there clinical trials I could join, for example of Savolitinib, Cabozantinib?
  2. 10.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 11.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 12.I read that “Small trials; most evidence is extrapolated from clear cell disease”. How does that affect my plan?
  5. 13.I read that “No approved therapy specific to FH-deficient cancer”. How does that affect my plan?

Tests and results to bring

Biomarker results to ask for: MET mutation, amplification or chromosome 7 gain, Fumarate hydratase loss (2SC immunohistochemistry) with germline FH testing, CDKN2A loss (poor outlook), Germline MET testing in young or multifocal disease.

Scans and tests linked to this cancer: Active surveillance.

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

  • Localised: Partial or radical nephrectomy, ablation or surveillance as for other kidney cancers; adjuvant therapy evidence is thin. (Thermal ablation (RFA, microwave, cryo), Active surveillance)
  • Metastatic: Cabozantinib first line (PAPMET); savolitinib for MET-driven tumours; immunotherapy combinations on single-arm data; clinical trials preferred. (Cabozantinib, Savolitinib, MET, Sunitinib, Pembrolizumab)
  • Hereditary syndromes: Early surgery for FH-deficient tumours because they spread early; surveillance in MET carriers; genetic counselling of relatives. (MET)

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call